Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300050 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1 study, sponsored by PATH.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT03300050 is a Phase 1 study that has completed, run by PATH. The registered enrollment target is 65 participants.
The verdict
NCT03300050, a Phase 1 study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
Interventions
- BIOLOGICAL cH8/1N1 LAIV
- BIOLOGICAL AS03-adjuvanted cH5/1N1 IIV
- BIOLOGICAL cH5/1N1 IIV
- BIOLOGICAL AS03-adjuvanted cH8/1N1 IIV
- BIOLOGICAL Normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300050
The ClinicalTrials.gov registry entry for NCT03300050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cH8/1N1 LAIV is the first listed.
NCT03300050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03300050 about?
NCT03300050 is a clinical study titled "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine". The clinical study will evaluate safety and the immune response of a prime- boost regimen with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza vaccine (IIV) boost with or without adjuvant.
What is the current status of trial NCT03300050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2017-10-10. Estimated completion is 2019-08-09.
What interventions are being tested in trial NCT03300050?
The interventions under investigation include: cH8/1N1 LAIV (BIOLOGICAL), AS03-adjuvanted cH5/1N1 IIV (BIOLOGICAL), cH5/1N1 IIV (BIOLOGICAL), AS03-adjuvanted cH8/1N1 IIV (BIOLOGICAL), Normal saline (BIOLOGICAL).
Who is sponsoring clinical trial NCT03300050?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.